Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sirius XM Holdings Inc (SIRI) vs 10X Genomics Inc (TXG) Price & Performance

Sirius XM Holdings IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Sirius XM Holdings Inc vs 10X Genomics Inc — how do they compare? Sirius XM Holdings Inc trades at $28.25 (market cap $9.70B), while 10X Genomics Inc trades at $58.16 (market cap $7.61B). The key difference: Sirius XM Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

SIRITXG
Market Cap
$9.70B$7.61B
Sector
MediaHealth
52-Week High
$32.59$58.57
52-Week Low
$19.92$11.34
Enterprise Value
$18.98B$7.14B
Dividend Yield
3.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sirius XM Holdings Inc

SIRI trades at $28.78, down 3.78% today, reflecting a bearish technical signal amid mixed earnings. The stock shows modest revenue growth and strong cash flow, with a P/E of 11.56 and P/B of 0.81 indicating potential undervaluation. Recent Q2 2026 earnings missed estimates, but the company raised full-year guidance, highlighting stable subscriber metrics and a dividend payout.

The outlook is cautiously optimistic, supported by analyst consensus of $33.17 price target and 58% buy ratings. Key risks include competitive pressures in satellite radio and high debt levels, though declining leverage and share buybacks offer upside. Investors should weigh stable cash generation against growth challenges.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About Sirius XM Holdings Inc

SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.

Read more on SIRI

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG